Relay Therapeutics (RLAY) Investor Presentation - Slideshow

Projected human oral bioavailability ~60% and half-life ~16h Target Inhibition and Efficacy RLY-2608 – First Mutant Selective Inhibitor to Enter the Clinic Limited potency against WT PI3Kα and other PI3K isoforms 30 Favorable Favorable Tolerability | --- | --- | |-----------------------------------------------------------|-------------------------------------------------------------------| | | | | Favorable Favorable Efficacy | | | Robust tumor regression at tolerable doses in mouse model | HCC1954 | | 2500 ...